

# A Randomized Comparative Study to Compare Karman's Cannula and Pipelle Biopsy for Evaluation of Abnormal Uterine Bleeding

Meeta Gupta, Puneeta Gupta<sup>1</sup>, Poonam Yadav<sup>2</sup>

Departments of Obst and Gynae and <sup>1</sup>Medicine, ASCOMS, Jammu, Jammu and Kashmir, <sup>2</sup>Department of Obst and Gynae, S.N. Medical College, Agra, Uttar Pradesh, India

Submitted: 19-Dec-2020  
Revised: 12-May-2021  
Accepted: 25-Jan-2022  
Published: 02-May-2022

## INTRODUCTION

Abnormal uterine bleeding (AUB) is an increasing health problem in the reproductive age group affecting nearly 9%–14% of women<sup>[1]</sup> with a significant impact on their quality of life.<sup>[2]</sup> AUB may be a part of disturbance in the menstrual cycle or sudden nonmenstrual bleeding, both of which require medical investigation in the form of endometrial sampling primarily to differentiate benign causes like hyperplasia from malignant causes like carcinoma.<sup>[3]</sup>

Invariably, dilatation and curettage (D and C) has been considered the gold standard for AUB investigation.<sup>[4]</sup> Besides, there are other methods for assessing the troubled

endometrium which include ultrasonography (USG), hysteroscopic biopsy, and endometrial sampling using the Vabra aspirator, Tao brush, SAP-1 brush sampler, Pipelle, or Karman cannula.<sup>[3,5]</sup> These devices are gaining importance due to the certain disadvantages of D and C such as time of procedure, cost, and invasiveness. In addition, D and C has an inherent risk of anesthesia-related complications, uterine infections, uterine perforations, and lacerations of the cervix.<sup>[6]</sup>

**Address for correspondence:** Dr. Meeta Gupta, Department of Obst and Gynae, ASCOMS, Jammu, Jammu and Kashmir, India.  
E-mail: meeta448@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow\_reprints@wolterskluwer.com

**How to cite this article:** Gupta M, Gupta P, Yadav P. A randomized comparative study to compare Karman's cannula and pipelle biopsy for evaluation of abnormal uterine bleeding. *J Mid-life Health* 2022;13:67-73.

## ABSTRACT

**Objectives:** This study aimed to compare the diagnostic accuracy, inadequate sampling, pain during the procedure (Visual Analog Scale [VAS] score), and ease of insertion of the Karman's cannula and Pipelle biopsy for patients with abnormal uterine bleeding (AUB). **Methods:** This prospective observational randomized comparative study included women of age more than 40 years with complaints of AUB. Two hundred and fifty women were randomly divided into two groups: (1) Group A ( $n = 125$ ) who underwent endometrial aspiration using Karman's cannula and (2) Group B ( $n = 125$ ) who underwent Pipelle endometrial sampling. Both the groups were followed by conventional dilation and curettage (D and C) which was considered the gold standard. Sensitivity, specificity, positive predictive value, and negative predictive value for differentiating benign and malignant conditions of endometrium were calculated. **Results:** Group B had a sensitivity of 89.29% followed by Group A (86.36%); on the other hand, Group A had a specificity of 96.08% followed by Group B (95.74%) ( $P > 0.05$ ). Inadequacy was comparable among the two groups with 1 inadequate in Group A and 3 inadequate in Group B. Mean VAS score was significantly lesser in Group A than Group B ( $4.5 \pm 2$  vs.  $5.8 \pm 2.1$ ,  $P < 0.0001$ ). Ease of insertion was similar in Groups A and B ( $P = 0.345$ ). **Conclusion:** Both procedures were equivalent in diagnostic accuracy, inadequacy, and ease of insertion. However, the use of Karman cannula resulted in less pain and is a much cheaper option in comparison to Pipelle. Overall, either procedure can be performed on an outpatient basis without cervical dilation and anesthesia and thus may be routinely used for women presenting with AUB.

**KEYWORDS:** Abnormal uterine bleeding, Karman's cannula, Pipelle

## Access this article online

### Quick Response Code:



**Website:** [www.jmidlifehealth.org](http://www.jmidlifehealth.org)

**DOI:** 10.4103/jmh.jmh\_292\_20

Karman's cannula is "a soft, flexible cannula" that works under the principle of suction. Its insertion involves no dilatation or anesthesia, making it a safe, feasible office procedure with minimal procedure time.<sup>[5]</sup>

Pipelle device, "a silastic flexible curette," is also a similar noninvasive method of endometrial sampling which does not require straightening of cervical fundus axis.<sup>[7]</sup> By its rotatory method, it samples around 5%–15% of the surface of the endometrium, thus establishing its use mainly in the global lesions rather than focal lesions.<sup>[8]</sup>

As both of them are effective and minimally invasive methods of endometrial aspiration, each of these methods has been studied individually in comparison with D and C, with results being in favor of their clinical use.<sup>[1,3,5,8-11]</sup> However, till date, there has been no head-to-head trial comparing both of them.

Hence, this study was planned to compare Karman's cannula versus Pipelle biopsy against the gold standard of conventional dilatation and curettage among patients of AUB. The study was done with an objective to compare the diagnostic accuracy, inadequate sampling, pain during the procedure, and ease of insertion of the devices.

## METHODS

A prospective observational randomized comparative study was conducted for a duration of 15 months from January 2019 to March 2020, which included women of age more than 40 years who presented to the outpatient department with complaints of AUB and underwent evaluation of the endometrium.

Any woman with pregnancy, pelvic inflammatory disease, gynecological malignancy, menopause or endometrial thickness <4 mm on transvaginal sonography (TVS) were excluded from the study. The institutional ethical clearance was obtained for the study from the institutional committee. The patients were explained about the procedure and written informed consent was obtained from them before enrolling them into the study.

The sample size calculation for the study was based on the values seen in the study by Vijay Zutshi *et al.*,<sup>[10]</sup> who observed that the adequacy of Karman cannula was 76.4%. Considering these values as reference and assuming a difference of 15% in the adequacy rate of Karman cannula group and Pipelle biopsy group, the minimum required sample size with 90% power of study and 5% level of significance is 121 patients in each study group. To reduce margin of error, total sample size taken was 250 (125 patients/group).

A clinical history about the age, parity, and any continuing hormone therapy was taken. Per speculum examination and per vaginal examination were done in detail of all the patients. TVS was done to evaluate the endometrial thickness before any intervention was planned.

The study population of 250 women were randomly divided into two groups: (1) Group A ( $n = 125$ ) who underwent endometrial aspiration using Karman's cannula (size of 4 mm without anesthesia and without cervical dilation) which was attached to the aspiration syringe and (2) Group B ( $n = 125$ ) who underwent Pipelle endometrial sampling under aseptic conditions without anesthesia or cervical dilation. After the insertion of the Pipelle device, the piston was fully withdrawn (to cause vacuum-assisted suction) and rotated to get the sample. The sample was collected in the initial part of the tube which was cut and sent for histopathology. The procedures were done by the principal investigator without blinding.


The block randomization for the two groups was done with sealed envelope system. In this method, ten sealed opaque envelopes were assigned A and B in 5 envelopes each, where A represented Karman cannula group and B represented Pipelle biopsy group. Once a patient agreed to enter the trial, an envelope was opened, and the patient was then offered the allocated group. In this technique, patients were randomized in a series of blocks of ten. A consort diagram of the randomization and patient flow is shown in Figure 1.

After the collection of the primary sample in both the groups, patients (of both the groups) further underwent cervical dilation and curettage under the use of 1% Xylocaine. The samples of Karman's cannula (Group A), Pipelle biopsy (Group B), and conventional D and C were collected separately in 10% formalin bottles and sent to laboratory for histopathological examination. For accuracy of the diagnosis, the histopathology reports of the D and C sample was considered to be the gold standard.

The primary outcome measures of our study were diagnostic accuracy of Karman endometrial aspiration versus Pipelle aspiration for differentiating benign and malignant conditions of endometrium. The secondary outcomes of the study were sample adequacy, ease of procedure, and pain score.

### Standards, definitions, and criteria

Endometrial lesions consisting of proliferative endometrium, secretory endometrium, endometritis, and hyperplasia without atypia were labeled as benign; while lesions consisting of hyperplasia with atypia,



**Figure 1: Consort flow diagram**

endometrial intraepithelial neoplasia, and endometrial carcinoma were labeled as malignant. The sample adequacy depended on the microscopic presence of intact endometrial glands in the background of stroma.<sup>[5]</sup> The ease of the procedure was adjudged by the clinician performing the procedure on a scale of 1–5. Pain was calculated using the Visual Analog Scale (VAS).

### Statistical analysis

The presentation of the categorical variables was done in the form of number and percentage (%). On the other hand, the presentation of the continuous variables was done as mean  $\pm$  standard deviation. The comparison of the variables which were quantitative in nature was analyzed using independent *t*-test (for the two groups) and for those which were qualitative in nature was analyzed using Chi-square test.

Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for each group, and McNemar test was used for comparison of sensitivity and specificity. The final analysis was done with the use of the Statistical Package for the Social Sciences, IBM manufacturer, Chicago, USA, version 21.0. For statistical purposes,  $P < 0.05$  was considered statistically significant.

## RESULTS

The mean age of the patients was comparable in Groups A and B ( $45.73 \pm 9.7$  vs.  $43.57 \pm 9.1$ ,  $P = 0.07$ ).


In both Groups A and B, most of the women were Para 1 (68% vs. 64%), followed by Para 2 (28% vs. 32%) and Para 3 (4% vs. 4%) ( $P = 0.785$ ) [Table 1].

Inadequacy was comparable among the two groups, with 1 (0.97%) inadequate in Group A and 3 (2.4%) inadequate in Group B ( $P = 0.622$ ), as shown in Figure 2.

Among the benign, 4 cases were incorrectly diagnosed as malignant in each Groups A and B, whereas among the malignant, 4 cases were incorrectly diagnosed as benign in each Groups A and B [Table 2].

Interpretation of the area under the receiver operating characteristic curve showed that the performance of Group A (area under the curve [AUC]: 0.91; 95% confidence interval [CI]: 0.85–0.96) and Group B (AUC: 0.93; 95% CI: 0.86–0.96) was outstanding. Group B had a sensitivity of 89.29% followed by Group A (86.36%). On the other hand, Group A had a specificity of 96.08% followed by Group B (95.74%). The highest PPV was found in Group B (86.21%) and the highest NPV was found in Group A (97.03%). There was no significant difference in sensitivity and specificity of Groups A and B ( $P > 0.05$ ) [Table 3].

The mean VAS score of the patients was lesser in Group A as compared to Group B ( $4.5 \pm 2$  vs.  $5.8 \pm 2.1$ ,  $P < 0.0001$ ). Ease of insertion was similar in Groups A and B as most of the patients have score



**Figure 2:** Comparison of inadequacy between Groups A and B

4 (43.20% vs. 48.80%,  $P = 0.345$ ) [Table 4]. There were no complications in either group.

## DISCUSSION

One of the important steps in evaluating the AUB for ruling out endometrial carcinoma is the endometrial biopsy; it is helpful in providing medical or conservative surgery and therefore unwarranted radical surgery can be prevented.

In the present study, we found that the diagnostic accuracy of both Karman cannula and Pipelle biopsy was comparable, with none of the procedures showing superiority over others.

The sensitivity, specificity, PPV, and NPV of Karman cannula were 86.36%, 96.08%, 82.61%, and 97.03%, respectively, for diagnosing malignant lesions. Among other studies which compared Karman with others, Tomar *et al.*<sup>[1]</sup> reported that Karman cannula had a sensitivity of 92.3%, specificity of 100%, PPV of 100%, and NPV of 99.56% for diagnosis of endometrial pathology, which was slightly higher than that of our study.

In our study, the Sn, Sp, PPV, and NPV of Pipelle biopsy were 89.29%, 95.74%, 86.21%, and 96.77%, respectively, for diagnosing malignant lesions. Compared to the present study, higher values were reported in a study done by Yasmin *et al.*,<sup>[12]</sup> as sensitivity, specificity, PPV, and NPV of Pipelle were 100%, 84%, 100%, and 95%, respectively. Abdelazim *et al.*<sup>[7]</sup> reported a 100% diagnostic accuracy for endometrial carcinoma for Pipelle device. Rachamalla *et al.*<sup>[13]</sup> reported that endometrial aspiration by Pipelle had a sensitivity of 93.4%, specificity of 100%, PPV of 100%, and NPV of 92.3%. Machado *et al.*<sup>[14]</sup> concluded that endometrial aspiration with Pipelle was 84.2% sensitive, 99.1% specific, and 96.9% accurate with 94.1% PPV and 93.7% NPV. However, lesser accuracy of Pipelle was reported

**Table 1: Demographic characteristics in Groups A and B**

Demographic characteristics	A (n=125)	B (n=125)
Age (years), mean±SD	45.73±9.7	43.57±9.1
Parity, n (%)		
Para 1	85 (68)	80 (64)
Para 2	35 (28)	40 (32)
Para 3	5 (4)	5 (4)

SD: Standard deviation

**Table 2: Comparison of diagnosis in the two groups**

Variables	A (n=125), n (%)	B (n=125), n (%)
Benign	103 (82.40)	96 (76.80)
Malignant	22 (17.60)	29 (23.20)

**Table 3: Sensitivity, specificity, positive predictive value, and negative predictive value of Groups A and B for predicting malignancy and comparison of sensitivity and specificity**

Malignancy	Group A	Group B
Sensitivity (95% CI)	86.36 (65.09-97.09)	89.29 (71.77-97.73)
Specificity (95% CI)	96.08 (90.26-98.92)	95.74 (89.46-98.83)
AUC (95% CI)	0.91 (0.85-0.96)	0.93 (0.86-0.96)
PPV (95% CI)	82.61 (61.22-95.05)	86.21 (68.34-96.11)
NPV (95% CI)	97.03 (91.56-99.38)	96.77 (90.86-99.33)
Diagnostic accuracy (%)	93.60	92.00
P value of sensitivity		0.607*
P value of specificity		0.854*

\*McNemar test. PPV: Positive predictive value, NPV: Negative predictive value, CI: Confidence interval, AUC: Area under the curve

**Table 4: Comparison of outcome between Groups A and B**

Variables	A (n=125)	B (n=125)	P*
VAS score, mean±SD	4.5±2	5.8±2.1	<0.0001
Ease of insertion, n (%)			
1	3 (2.40)	5 (4)	0.345
2	7 (5.60)	7 (5.60)	
3	34 (27.20)	37 (29.60)	
4	54 (43.20)	61 (48.80)	
5	27 (21.60)	15 (12)	

\*Independent t-test, SD: Standard deviation, VAS: Visual Analog Scale

by Ilavarasi *et al.*<sup>[15]</sup> Similarly, less accuracy of Pipelle was reported by Demirkiran *et al.*,<sup>[16]</sup> as sensitivity in detection of hyperplasia and atypia was 67% and 75%, respectively.

The varying diagnostic accuracy can be ascribed to the technique itself whereby many endometrial glands may be deformed or the aspirated sample might be inadequate for reporting.

Reason for inadequacy with Pipelle may be because of the less expertise as the procedure is relatively new and not used in routine.<sup>[3]</sup> However, literature review

shows that factors that affect the insufficient sampling are rarely evaluated. As per our experience, it can be said that the chances of obtaining a sufficient sample are higher in correlation with increasing endometrial thickness. As reported by Bakour *et al.*,<sup>[17]</sup> endometrial thickness of <5 mm on USG forms a standard cutoff for insufficient sampling.<sup>[18]</sup>

In the present study, one case (0.97%) was inadequate in the Karman cannula group and three cases (2.4%) in the Pipelle group. Among other studies on Karman, the inadequacy rate has been reported to range from 2% to 24%,<sup>[1,5,10,19-22]</sup> and for Pipelle, it has been reported in the range of 2% to 28.8%.<sup>[13,23-27]</sup> Since we frequently use Karman cannula, the inadequacy was lower in that group. Moreover, there has been an increasing use of Pipelle at our institute because of increasing awareness and demand which might have accounted for a lower inadequacy in that group as well. We propose the regular use of these endometrial aspiration devices as they are safe with good accuracy and low inadequacy.

During procedure of endometrial aspiration with Karman cannula and Pipelle biopsy, pain can be experienced due to cramping.<sup>[5]</sup> In our study, the mean VAS score of the patients was lesser in the Karman cannula group compared to the Pipelle group ( $4.5 \pm 2$  vs.  $5.8 \pm 2.1$ ,  $P < 0.0001$ ). Although both the techniques are done without dilation and anesthesia, both are considered nonpainful. However, individuals may experience different levels of pain as per the threshold. Interestingly, in both the groups, the pain intensity was termed to be mild. In the study by Gupta *et al.*,<sup>[3]</sup> median VAS score in nulligravida and multigravida was 4 and 2 after the use of Pipelle, which is almost similar to the present study. They also stressed that VAS scores in the Pipelle group were less than the D and C group, suggesting that it is a less painful procedure as compared to the standard D and C. Rauf *et al.*<sup>[24]</sup> compared Pipelle device and D and C and reported that Pipelle caused significantly less pain. Balaram *et al.*<sup>[28]</sup> also reported similar findings as, during Pipelle curettage, very few patients experienced mild pain that was well tolerated.

In the study by Zutshi *et al.*,<sup>[10]</sup> no significant difference in pain score was observed in Karman cannula and Endosampler groups, with both showing less pain. Mathew and Thomas<sup>[29]</sup> observed that most of the patients required no analgesics after Karman cannula use. Thus, it can be said that Karman cannula and Pipelle use is associated with less pain, however, between both of them, we advocate Karman cannula in terms of pain threshold. Future studies are required to find the factors affecting the pain during these procedures and maneuvers to further reduce the pain below the level of 5 VAS score.

Another aspect that carries importance during the procedure is the ease of insertion. In the present study, ease of insertion was similar in both the Karman cannula and Pipelle groups. Indirectly, other studies have shown that the use of these devices provides ease of procedure in comparison to the conventional D and C.

Nama *et al.*<sup>[5]</sup> compared D and C and Karman endometrial sampling and found that in D and C, 11% of patients were termed as not easy and 1% in Karman endometrial sampling were termed not easy. In a study, Navakumar *et al.*<sup>[30]</sup> reported that Pipelle aspiration was easy in most of the patients when compared with D and C. Zutshi *et al.*<sup>[10]</sup> did not observe any difference in terms of ease of insertion in the Karman cannula group on the basis of experience of residents, while residents with >2 years' experience can more easily perform D and C. Even Balaram *et al.*<sup>[28]</sup> found ease of doing procedure with Pipelle as much easier than D and C. Findings of the studies indicate that Karman cannula and Pipelle are much easy to use than other devices/methods. The experience of the treating physician carries paramount importance while performing the procedure.

There is a requirement of an accurate and low-cost device for endometrial aspiration with specimen adequacy and higher sensitivity for diagnosis. In India, the cost of Karman cannula is Rupees 8–15/piece, and the average cost of a Pipelle sampling is Rs. 250.<sup>[31]</sup> Tansathit *et al.*<sup>[22]</sup> reported that the use of Karman cannula for aspiration decreases the cost of the diagnostic workup for AUB. Zutshi *et al.*<sup>[10]</sup> also found Karman cannula to be five times cheaper than Endosampler for endometrial biopsy.

Although we found no complications with either procedure, literature reports the possibility of prolonged bleeding and slight chances of infection with Karman cannula<sup>[22]</sup> and concerns related to adequacy of the sample and nonsampling of focal intrauterine lesions with Pipelle.<sup>[3]</sup>

The study had certain limitations. First, the cost of the procedure was not taken into account as the devices were procured from the hospital without any additional cost for the patient. However, the high cost of Pipelle in comparison to Karman cannula can be a limiting factor for its use. Second, the diagnostic accuracy of both aspirators was compared against conventional D and C rather than endometrial biopsy or hysterectomy. Third, the experience of the physician performing the procedure was not compared since it may significantly affect the inadequacy of the procedure.

In spite of the limitations, the strength of the study was that it was a prospective study and a single-center

study where samples were collected by an experienced physician and evaluated by an experienced pathologist. Furthermore, to the best of our knowledge, this seems to be the first study that compared the efficacy of Karman cannula and Pipelle.

## CONCLUSION

It can be concluded that endometrial aspiration with Karman cannula resulted in no significant difference with respect to diagnostic accuracy, inadequacy, and ease of insertion in comparison with Pipelle biopsy. However, the use of Karman cannula resulted in less pain and is a much cheaper option in comparison to Pipelle.

Overall, either procedure may be routinely used for endometrial aspiration for a histopathological diagnosis. These procedures can be performed on an outpatient basis without cervical dilation and anesthesia. Therefore, women presenting with AUB can be evaluated by a family physician who can provide primary care without hospitalization.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Tomar NS, Sandhu S, Mahipal S, Chaudhary A. A comparative study to evaluate endometrial aspiration using Karman's cannula versus dilatation and curettage in cases of abnormal uterine bleeding. *Int J Reprod Contracept Obstet Gynecol* 2020;9:1218-21.
- Côté I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. *Obstet Gynecol* 2002;100:683-7.
- Gupta M, Yadav P, Jamwal N, Gupta V. A study to compare the efficacy, inadequacy and patient knowledge of pipelle and dilatation and curettage (D&C) for patients with abnormal uterine bleeding. *New Indian J OBGYN* 2021;7:206-11.
- Cooper JM, Erickson ML. Endometrial sampling techniques in the diagnosis of abnormal uterine bleeding. *Obstet Gynecol Clin North Am* 2000;27:23544.
- Nama A, Kochar S, Suthar N, Kumar A, Solanki K. Accuracy of Karman endometrial aspiration in comparison to conventional D and C in women with AUB at tertiary care hospital in North West Rajasthan. *J Family Med Prim Care* 2020;9:3496-501.
- Telner DE, Jakubovicz D. Approach to diagnosis and management of abnormal uterine bleeding. *Can Fam Physician* 2007;53:58-64.
- Abdelazim IA, Aboelezz A, Abdulkareem AF. Pipelle endometrial sampling versus conventional dilatation & curettage in patients with abnormal uterine bleeding. *J Turk Ger Gynecol Assoc* 2013;14:1-5.
- Chandrakumari AS, Lingappa HA, Singaravel SD. Evaluation of diagnostic efficacy of pipelle endometrial sampling in abnormal uterine bleeding. *J Clin Diagn Res* 2018;12:EC01-4.
- Hadisaputra W, Affandi B, Rogers PA. Endometrial biopsy collection from women receiving Norplant®. *Med J Indones* 1998;7:25-8.
- Zutshi V, Gupta M, Kaur P, Malik A, Zaheer S, Gambhir P. Office endometrial sampling: A comparison between endosampler and karman cannula number 4. *Int J Reprod Contracept Obstet Gynecol* 2018;7:3965-8.
- Patil P, Venigalla S, Kumar ML, Raju K. A comparative evaluation of the three different methods of endometrial sampling in the diagnosis of perimenopausal bleeding. *Clin Gynecol Obstet* 2014;3:133-7.
- Yasmin F, Farrukh R, Kamal F. Efficacy of pipelle as a tool for endometrial biopsy. *Biomedica* 2007;23:116-9.
- Rachamalla L, Bhavani V, Byna P. Histological correlation of pipelle endometrial sampling with dilatation and curettage in abnormal uterine bleeding. *Int J Reprod Contracept Obstet Gynaecol* 2015;4:1324-9.
- Machado F, Moreno J, Carazo M, León J, Fiol G, Serna R. Accuracy of endometrial biopsy with the Cornier pipelle for diagnosis of endometrial cancer and atypical hyperplasia. *Eur J Gynaecol Oncol* 2003;24:279-81.
- Ilavarasi CR, Jyothi GS, Alva NK. Study of the efficacy of pipelle biopsy technique to diagnose endometrial diseases in abnormal uterine bleeding. *J Midlife Health* 2019;10:75-80.
- Demirkiran F, Yavuz E, Erenel H, Bese T, Arvas M, Sanioglu C. Which is the best technique for endometrial sampling? Aspiration (pipelle) versus dilatation and curettage (D&C). *Arch Gynecol Obstet* 2012;286:1277-82.
- Bakour SH, Khan KS, Gupta JK. Controlled analysis of factors associated with insufficient sample on outpatient endometrial biopsy. *BJOG* 2000;107:1312-4.
- Ates A, Karasu AF, Cali H, Soyman Z. Factors associated with insufficient endometrial sampling in postmenopausal women. *Med Bull Haseki* 2020;58:65-71.
- Handa U, Bansal C, Aggarwal P, Huria A, Mohan H. Diagnostic utility of endometrial aspiration cytology in women with abnormal uterine bleeding. *J Midlife Health* 2018;9:140-4.
- Saikia JB, Sharma A. Endometrial aspiration cytology by Karman's cannula with histopathological correlation. *Int J Sci Res* 2017;6:167983.
- Kenchappa S, Gandhi N, Shukla A, Rathore A. Diagnostic efficacy endometrial aspiration cytology in gynecological pathology. *Indian J Pathol Oncol* 2017;4:51722.
- Tansathit T, Chichareon S, Tocharoenvanich S, Dechsukhum C. Diagnostic evaluation of Karman endometrial aspiration in patients with abnormal uterine bleeding. *J Obstet Gynaecol Res* 2005;31:480-5.
- Moghaddam TG, Hedayatifar F, Nouri B. Comparing the pipelle with dilatation and curettage (D&C) in diagnostic power of sampling for evaluating the patients with abnormal uterine bleeding. *Int J Med Invest* 2018;7:56-67.
- Rauf R, Shaheen A, Sadia S, Waqar F, Zafar S, Sultana S, et al. Outpatient endometrial biopsy with pipelle vs. diagnostic dilatation and curettage. *J Ayub Med Coll Abbottabad* 2014;26:145-8.
- Rezk M, Sayyed T, Dawood R. The effectiveness and acceptability of pipelle endometrial sampling versus classical dilatation and curettage: A three-year observational study. *Gynecol Obstet Invest* 2016;81:537-42.
- Fakhar S, Saeed G, Khan AH, Alam AY. Validity of pipelle endometrial sampling in patients with abnormal uterine bleeding. *Ann Saudi Med* 2008;28:188-91.
- Singh P. Abnormal uterine bleeding – Evaluation by endometrial aspiration. *J Midlife Health* 2018;9:32-5.

28. Balam MS, Shinde RR, Babu CS, Mohamed Mubasher HM, Shinde RV. Role of pipelle versus dilatation and curettage in tissue diagnosis abnormal uterine bleeding. *Int J Res Med Sci* 2020;8:3223-9.
29. Mathew SM, Thomas P. A prospective study on the efficacy of pipelle biopsy to diagnose endometrial pathology in patients with abnormal uterine bleeding. *Int J Reprod Contracept Obstet Gynecol* 2019;8:4238-43.
30. Navakumar N, Dinesh D, Devi PK. Endometrial tissue sampling using pipelle versus dilatation and curettage for the assessment of endometrium in patients of perimenopausal and postmenopausal age: A prospective study. *Int J Reprod Contracept Obstet Gynecol* 2018;7:39519.
31. Mamatha S, Lakshmikantha G. A comparative study between pipelle endometrial sampling and dilatation curettage in abnormal uterine bleeding. *Int J Clin Obstet Gynaecol* 2020;4:171-6.